Different suitable glioblastoma-specific cell surface antigens have been identified as targets for CAR T cell therapy, such as the epidermal growth factor receptor vIII (EGFRvIII), HER2, IL-13 receptor α chain 2 (IL13Rα2), B7-H3, including disialoganglioside GD2 which have undergone both animal trials and subsequent clinical trials7–9. This evidence concerns the gene IL13RA2 and glioblastoma.